The Global Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1943.69 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031.

Key players operating in the Transthyretin Amyloid Cardiomyopathy Treatment market are DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin, Silk€TMn, HoMedics USA LLC, PMD Beauty, Dermaglow, ImageDerm Inc., Clairderm Medical Aesthetics, Sylvan Company, Altair Instruments, Koninklijke Philips, Microderm GLO Skincare USA, Silhouet-Tone, and Edge Systems LLC. (HydraFacial), among others.

Key players are focusing on developing innovative gene therapies such as RNA interference (RNAi) based treatments to provide attractive prospects for patients diagnosed with transthyretin amyloid cardiomyopathy. For instance, the gene silencing therapy developed by Alnylam Pharmaceuticals called Oxpimod received approval from the U.S. FDA in May 2022 for the treatment of Transthyretin Amyloid Cardiomyopathy Treatment Market Size .

The global Transthyretin Amyloid Cardiomyopathy Treatment market is being driven by the increasing incidence of cardiomyopathy worldwide. According to recent studies, the worldwide prevalence of cardiomyopathy is estimated to be 1 in every 500 individuals. Moreover, men have a slightly higher chance of developing this condition compared to women. As the global geriatric population continues to rise, the risk of developing age-related cardiomyopathies such as transthyretin amyloid cardiomyopathy is also anticipated to increase in the coming years.

The market is also being driven by growing awareness about the availability of effective treatment options and the need for early diagnosis of cardiomyopathy. Advancements in genetic testing technologies have enabled faster and more accurate diagnosis of cardiomyopathies caused by gene mutations like transthyretin amyloid cardiomyopathy. Additionally, various non-profit organizations are undertaking initiatives to spread awareness about heart muscle diseases like cardiomyopathy among the general population as well as healthcare providers. This is further expected to boost the early detection and management of transthyretin amyloid cardiomyopathy worldwide.

Market drivers: The global Transthyretin Amyloid Cardiomyopathy Treatment market is primarily driven by the increasing prevalence of cardiomyopathy diseases due to rising geriatric population globally. Additionally, continuous advancements in genetic testing technologies facilitate faster and accurate diagnosis of transthyretin amyloid cardiomyopathy. Rising awareness about the disease condition and availability of effective treatment options is driving more patients to seek medical help in early stages. Increasing healthcare expenditure in developed regions and government support towards cardiac health programs are also propelling the market growth.
Get more insights on Transthyretin Amyloid Cardiomyopathy Treatment Market